Tavaborole for the treatment of onychomycosis

Bibliography

• Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998;38(6 Pt 2):S77-86
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43:641-8
   PubMed Web of Science ®Google Scholar
• Thomas J, Jacobson GA, Narkowicz CK, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther 2010;35(5):497-519
   PubMed Web of Science ®Google Scholar
• Di Chiacchio N, Suarez MV, Madeira CL, Loureiro WR. An observational and descriptive study of the epidemiology of and therapeutic approach to onychomycosis in dermatology offices in Brazil. An Bras Dermatol 2013;88(Suppl 1):3-11
   PubMedGoogle Scholar
• Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997;36(3 Pt 1):395-402
   PubMed Web of Science ®Google Scholar
• Rodríguez-Pazos L, Pereiro-Ferreirós MM, Pereiro M Jr, Toribio J. Onychomycosis observed in children over a 20-year period. Mycoses 2011;54:450-3
   PubMed Web of Science ®Google Scholar
• Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997;133:1172-3
   PubMed Web of Science ®Google Scholar
• Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43:244-8
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11:415-29
   PubMed Web of Science ®Google Scholar
• Baran R. The nail in the elderly. Clin Dermatol 2011;29:54-60
   PubMed Web of Science ®Google Scholar
• Cathcart S, Cantrell W, Elewski BE. Onychomycosis and diabetes. J Eur Acad Dermatol Venereol 2009;23:1119-22
   PubMed Web of Science ®Google Scholar
• Baran R, Hay RJ, Tosti A, Haneke E. A new classification of onychomycosis. Br J Dermatol 1998;139:567-71
   PubMed Web of Science ®Google Scholar
• Zaias N. Onychomycosis. Dermatol Clin 1985;3:445-60
   PubMed Web of Science ®Google Scholar
• Piraccini BM, Tosti A. White superficial onychomycosis: epidemiological, clinical, and pathological study of 79 patients. Arch Dermatol 2004;140:696-701
   PubMed Web of Science ®Google Scholar
• Piraccini BM, Lorenzi S, Tosti A. ‘Deep’ white superficial onychomycosis dueto molds. J Eur Acad Dermatol Venereol 2002;16:532-3
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000;42(2 Pt 1):217-24
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11:415-29
   PubMed Web of Science ®Google Scholar
• Moreno-Coutiño G, Arenas R, Reyes-Terán G. Clinical presentation of onychomycosis in hiv/aids: a review of 280 mexican cases. Indian J Dermatol 2011;56:120-1
   PubMedGoogle Scholar
• de Lima AM, da Rocha SP, Reis Filho EG, et al. Study of dermatoses in kidney transplant patients. An Bras Dermatol 2013;88:361-7
   PubMed Web of Science ®Google Scholar
• Mayser P, Freund V, Budihardja D. Toenail onychomycosis in diabetic patients: issues and management. Am J Clin Dermatol 2009;10:211-20
   PubMed Web of Science ®Google Scholar
• Lamb FM, Ottonelli Stopiglia CD, Vetoratto G, et al. Frequency of onychomycoses in chronic renal failure patients undergoing hemodialysis in Porto Alegre, Brazil. Acta Dermatovenerol Croat 2013;21:19-23
   PubMed Web of Science ®Google Scholar
• Fukunaga A, Washio K, Ogura K, et al. Onychomycosis as a warning sign for peripheral arterial disease. Acta Derm Venereol 2013;93:747-8
   PubMed Web of Science ®Google Scholar
• Abdelaziz AM, Mahmoud KM, Elsawy EM, Bakr MA. Nail changes in kidney transplant recipients. Nephrol Dial Transplant 2010;25:274-7
   PubMed Web of Science ®Google Scholar
• Ozkan F, Ozturk P, Ozyurt K, et al. Frequency of peripheral arterial disease and venous insufficiency in toenail onychomycosis. J Dermatol 2013;40:107-10
   PubMed Web of Science ®Google Scholar
• Zaias N, Rebell G. Chronic dermatophytosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996;35(3 Pt 2):S17-20
   PubMed Web of Science ®Google Scholar
• Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol 2010;28:151-9
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000;1:19-26
   PubMedGoogle Scholar
• Lamisil® (terbinafine hydrochloride) Tablets [Prescribing Information 2013]. Novartis Pharmaceuticals Corporation; East Hanover, NJ
   Google Scholar
• Sporanox® (itraconazole) Capsules. [Prescribing Information 2012]. Janssen Pharmaceuticals, Inc; Titusville, NJ
   Google Scholar
• Gupta AK, Konnikov N, Lynde CW, et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. Eur J Dermatol 1999;9:633-8
   PubMed Web of Science ®Google Scholar
• Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Dermatol Venereol 1996;76:82-3
   PubMed Web of Science ®Google Scholar
• Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother 2013;57:1610-16
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. itraconazole in onychomycosis. Br J Dermatol 1999;141(Suppl 56):5-14
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000;1:19-26
   PubMedGoogle Scholar
• Baker SJ, Huib X, Maibach HI. Progress on new therapeutics for fungal nail infections. Ann Rep Med Chem 2005;40:323-35
   Web of Science ®Google Scholar
• Kobayashi Y, Komatsu T, Sumi M, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci 2004;21:471-7
   PubMed Web of Science ®Google Scholar
• Penlac® Nail Lacquer (ciclopirox) Topical Solution PI. Dermik Laboratories, A Division of Aventis Pharmaceuticals Inc; Berwyn, PA
   Google Scholar
• Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992;17(Suppl 1):44-9
   PubMed Web of Science ®Google Scholar
• Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992;17(Suppl 1):41-3
   PubMed Web of Science ®Google Scholar
• Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013;68:600-8
   PubMed Web of Science ®Google Scholar
• Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998;139:665-71
   PubMed Web of Science ®Google Scholar
• Elewski BE, Rich P, Tosti A, et al. Onchomycosis: an overview. J Drugs Dermatol 2013;12:S96-103
   PubMedGoogle Scholar
• Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 2003;207:255-60
   PubMed Web of Science ®Google Scholar
• Baker SJ, Zhang YK, Akama T, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 2006;49:4447-50
   PubMed Web of Science ®Google Scholar
• Barak O, Loo DS. AN-2690, a novel antifungal for the topical treatment of onychomycosis. Curr Opin Investig Drugs 2007;8:662-8
   PubMed Web of Science ®Google Scholar
• Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007;316:1759-61
   PubMed Web of Science ®Google Scholar
• Alley MR, Baker SJ, Beutner KR, Plattner J. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 2007;16:157-67
   PubMed Web of Science ®Google Scholar
• Hui X, Baker SJ, Wester RC, et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007;96:2622-31
   PubMed Web of Science ®Google Scholar
• Data on file. Study Report 002-NCL PK-069-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
   Google Scholar
• Data on file. Study Report 002-NCL PP-002-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
   Google Scholar
• Data on file. Study Report 002-NCL PP-014-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
   Google Scholar
• Data on file. Study Report 002-CLN PK-005-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
   Google Scholar
• Data on file. Study Report 002-CLN PK-003-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
   Google Scholar
• Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007;56:939-44
   PubMed Web of Science ®Google Scholar
• Zane LT, Pollak RA. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. Presented: National American Podiatric Medical Association Annual Scientific Meeting; 16 – 19 August 2012; Washington, DC
   Google Scholar
• Toledo-Bahena M, Barba-Gomez JF, Jones T, et al. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. Presented: Society of Dermatology Physician Assistants; 13 November 2013; Atlanta GA
   Google Scholar
• Elewski BE, Rich P, Wiltz H, et al. Effectiveness and safety of tavaborole, a novel boron-based molecule for the topical treatment of toenail onychomycosis: results from two phase 3 studies. Presented: Winter Clinical Dermatology Conference; 17 – 22 January 2014; Kona Coast, HI
   Google Scholar
• Data on file. Study Report 002-CLN CL-007-01. Anacor Pharmaceuticals, Inc., Palo Alto, CA
   Google Scholar